metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2) 1
colorectal cancer (CRC)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone

versus all
vs immune chekpoint inhibitors
vs others immune checkpoint inhibitors
vs brentuximab vedotin

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open